Logo image
Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models
Journal article   Open access   Peer reviewed

Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models

Yanjun Zhang, Jing Sun, Jian Zheng, Suxiang Li, Haiyue Rao, Jun Dai, Zhaoyong Zhang, Yanqun Wang, Donglan Liu, Zhao Chen, …
Advanced science, Vol.11(9), e2303366
03/2024
DOI: 10.1002/advs.202303366
PMCID: PMC10916629
PMID: 38105421
url
https://doi.org/10.1002/advs.202303366View
Published (Version of record) Open Access

Abstract

To combat SARS-CoV-2 variants and MERS-CoV, as well as the potential re-emergence of SARS-CoV and spillovers of sarbecoviruses, which pose a significant threat to global public health, vaccines that can confer broad-spectrum protection against betacoronaviruses (β-CoVs) are urgently needed. A mosaic ferritin nanoparticle vaccine is developed that co-displays the spike receptor-binding domains of SARS-CoV, MERS-CoV, and SARS-CoV-2 Wild-type (WT) strain and evaluated its immunogenicity and protective efficacy in mice and nonhuman primates. A low dose of 10 µg administered at a 21-day interval induced a Th1-biased immune response in mice and elicited robust cross-reactive neutralizing antibody responses against a variety of β-CoVs, including a series of SARS-CoV-2 variants. It is also able to effectively protect against challenges of SARS-CoV, MERS-CoV, and SARS-CoV-2 variants in not only young mice but also the more vulnerable mice through induction of long-lived immunity. Together, these results suggest that this mosaic 3-RBD nanoparticle has the potential to be developed as a pan-β-CoV vaccine.
mosaic RBD nanoparticle vaccine coronavirus

Details

Metrics

Logo image